Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pluripotent stem cells (PSCs) are a unique class of undifferentiated cells characterized by their capacity for indefinite self-renewal and their potential to differentiate into any cell type derived from the three primary germ layers: ectoderm, endoderm, and mesoderm [NIH Stem Cell Information, 2016]. This category primarily encompasses embryonic stem cells (ESCs), obtained from the inner cell mass of a blastocyst, and induced pluripotent stem cells (iPSCs), which are adult somatic cells genetically reprogrammed to a pluripotent state using specific transcription factors [Takahashi & Yamanaka, Cell, 2006]. While PSCs are not traditional molecular targets like receptors or enzymes, they represent a revolutionary platform in regenerative medicine and drug discovery for treating conditions such as Parkinson's disease and heart failure [Lee et al., Nature Reviews Drug Discovery, 2013]. Small molecules are frequently employed to manipulate the signaling networks—such as the Wnt and TGF-beta pathways—that govern their fate and maintain their pluripotency [Wu & Belmonte, Nature Reviews Genetics, 2015]. However, the clinical application of PSC-derived therapies is currently limited by significant safety hurdles, most notably the risk of tumorigenesis and the potential for teratoma formation if undifferentiated cells remain in the transplant [Bulic-Jakus et al., World Journal of Stem Cells, 2016].
Drugs and small molecules interact with pluripotent cells by modulating key intracellular signaling pathways, such as Wnt/beta-catenin, TGF-beta/Smad, and Rho-associated protein kinase (ROCK), or by acting as epigenetic modifiers to maintain the undifferentiated state or direct lineage-specific differentiation into specialized cell types.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pluripotent stem cell (PSC) (PSC).